Cyclo(Prolylglycyl)

Summary

Cyclo(Prolylglycyl) (CHEMBL360216) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 154.17 Da · C7H10N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL360216
Name	Cyclo(Prolylglycyl)
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	126154
Molecular formula	C7H10N2O2
Molecular weight	154.17
InChIKey	OWOHLURDBZHNGG-YFKPBYRVSA-N

SMILES: C1C[C@H]2C(=O)NCC(=O)N2C1

IUPAC name: (8aS)-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione

Also known as: Cyclic glycine-proline, Cyclo(prolylglycyl), Na 831, NA-831, NA831, Traneurocin, cyclo-(glycyl-L-prolyl), CYCLO(PROLYLGLYCYL)

Patent coverage: 64 distinct patent families (163 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04452565	PHASE2/PHASE3	UNKNOWN	NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04540185	PHASE3	UNKNOWN	A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).